Novel mechanism of MYC deregulation in Multiple Myeloma
Rahmat, M.; Clement, K.; Alberge, J.-B.; Sklavenitis-Pistofidis, R.; Kodgule, R.; Fulco, C.; Heilpern-Mallory, D.; Nilsson, K.; Dorfman, D.; Engreitz, J.; Getz, G.; Pinello, L.; Ryan, R.; Ghobrial, I. M.
Show abstract
MYC deregulation occurs in 67% of multiple myeloma (MM) cases and associates with progression and worse prognosis in MM. Enhanced MYC expression is known to be driven by translocation or amplification events, but it only occurs in 40% of MM patients. Here, we describe a new mechanism of MYC regulation, whereby epigenetic regulation of MYC by increased accessibility of a cell-type specific enhancer leads to increased MYC expression. We found enhancer activity does not associate with enhancer hijacking events. We identified specific binding of c-MAF, IRF4, and SPIB transcription factors to the enhancer can activate MYC. In addition, we discovered focal amplification of this specific enhancer in approximately 4% of MM patients. Together, our findings define a new epigenetic mechanism of MYC deregulation in MM beyond known translocations or amplifications and point to the importance of non-coding regulatory elements and their associated transcription factor networks as drivers of MM progression.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Aberrant non-canonical NF-kappaB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma 98%
- Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma 96%
- EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition 96%
Similar papers in this journal
- Systems medicine dissection of chromosome 1q amplification reveals oncogenic regulatory circuits and informs targeted therapy in cancer 97%
- Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression between patients 95%
- KDM6A Regulates Immune Response Genes in Multiple Myeloma 95%
Similar papers in this journal
- The SAGA acetyltransferase module is required for the maintenance of MAF and MYC oncogenic gene expression programs in multiple myeloma 95%
- The conserved N-terminal SANT1-binding domain (SBD) of EZH2 Regulates PRC2 Activity 95%
- Chronic Interferon Stimulated Gene Transcription Promotes Oncogene Induced Breast Cancer 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.